Skip to content
10-Q

Quarterly Report

Pear Therapeutics, Inc.

0001835567-22-000076

← back to feed
Filed
Nov 14, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2022 · Nov 10, 2022 139.54M sh
Shares Diluted Q3 2022 · Sep 30, 2022 138.96M sh
Shares Diluted Q3 2022 · Sep 30, 2022 138.37M sh
Shares Diluted Q3 2022 · Sep 30, 2021 112.24M sh
Shares Diluted Q3 2022 · Sep 30, 2021 110.96M sh
Capex Q3 2022 · Sep 30, 2022 $2.4M
Capex Q3 2022 · Sep 30, 2021 $2.38M
Operating Cash Flow Q3 2022 · Sep 30, 2022 −$89.62M
Operating Cash Flow restated Q3 2022 · Sep 30, 2021 −$69.2M
Long Term Debt Q3 2022 · Sep 30, 2022 $0
Short Term Debt Q3 2022 · Sep 30, 2022 $27.46M
Short Term Debt Q3 2022 · Dec 31, 2021 $26.99M
Short Term Investments Q3 2022 · Sep 30, 2022 $23.93M
Short Term Investments Q3 2022 · Dec 31, 2021 $5M
Cash And Equivalents Q3 2022 · Sep 30, 2022 $59.69M
Cash And Equivalents Q3 2022 · Dec 31, 2021 $169.57M
Stockholders Equity Q3 2022 · Sep 30, 2022 $52.25M
Stockholders Equity Q3 2022 · Jun 30, 2022 $79.04M
Stockholders Equity Q3 2022 · Mar 31, 2022 $69.51M
Stockholders Equity Q3 2022 · Dec 31, 2021 $90.43M
Stockholders Equity restated Q3 2022 · Sep 30, 2021 $27.96M
Stockholders Equity restated Q3 2022 · Jun 30, 2021 $58.2M
Stockholders Equity restated Q3 2022 · Mar 31, 2021 $85.56M
Stockholders Equity restated Q3 2022 · Dec 31, 2020 $87.12M
Current Liabilities Q3 2022 · Sep 30, 2022 $48.16M
Current Liabilities Q3 2022 · Dec 31, 2021 $47.17M
Total Liabilities Q3 2022 · Sep 30, 2022 $67.49M
Total Liabilities Q3 2022 · Dec 31, 2021 $106.73M
Current Assets Q3 2022 · Sep 30, 2022 $98.87M
Current Assets Q3 2022 · Dec 31, 2021 $185.24M
Total Assets Q3 2022 · Sep 30, 2022 $119.74M
Total Assets Q3 2022 · Dec 31, 2021 $197.16M
Eps Diluted Q3 2022 · Sep 30, 2022 −$0.22
Eps Diluted Q3 2022 · Sep 30, 2022 −$0.35
Eps Diluted Q3 2022 · Sep 30, 2021 −$0.28
Eps Diluted Q3 2022 · Sep 30, 2021 −$0.76
Eps Basic Q3 2022 · Sep 30, 2022 −$0.22
Eps Basic Q3 2022 · Sep 30, 2022 −$0.35
Eps Basic Q3 2022 · Sep 30, 2021 −$0.28
Eps Basic Q3 2022 · Sep 30, 2021 −$0.76
Sga Expense Q3 2022 · Sep 30, 2022 $17.77M
Sga Expense Q3 2022 · Sep 30, 2022 $61.51M
Sga Expense Q3 2022 · Sep 30, 2021 $17.97M
Sga Expense Q3 2022 · Sep 30, 2021 $45.81M
Rd Expense Q3 2022 · Sep 30, 2022 $10.39M
Rd Expense Q3 2022 · Sep 30, 2022 $36.37M
Rd Expense Q3 2022 · Sep 30, 2021 $9.58M
Rd Expense Q3 2022 · Sep 30, 2021 $24.94M
Net Income Q3 2022 · Sep 30, 2022 −$30.72M
Net Income Q3 2022 · Sep 30, 2022 −$49.12M
Net Income Q3 2022 · Jun 30, 2022 $5.46M
Net Income Q3 2022 · Mar 31, 2022 −$23.86M
Net Income restated Q3 2022 · Sep 30, 2021 −$31.3M
Net Income restated Q3 2022 · Sep 30, 2021 −$83.89M
Net Income restated Q3 2022 · Jun 30, 2021 −$28.2M
Net Income restated Q3 2022 · Mar 31, 2021 −$24.39M
Operating Income Q3 2022 · Sep 30, 2022 −$26.63M
Operating Income Q3 2022 · Sep 30, 2022 −$94.19M
Operating Income restated Q3 2022 · Sep 30, 2021 −$28.35M
Operating Income restated Q3 2022 · Sep 30, 2021 −$71.45M
Cost Of Revenue Q3 2022 · Sep 30, 2022 $2.56M
Cost Of Revenue Q3 2022 · Sep 30, 2022 $6.44M
Cost Of Revenue Q3 2022 · Sep 30, 2021 $2.12M
Cost Of Revenue Q3 2022 · Sep 30, 2021 $3.59M
Revenue Q3 2022 · Sep 30, 2022 $4.08M
Revenue Q3 2022 · Sep 30, 2022 $10.13M
Revenue Q3 2022 · Sep 30, 2021 $1.31M
Revenue Q3 2022 · Sep 30, 2021 $2.89M